TY - JOUR
T1 - Inflammasomes as biomarkers and therapeutic targets in traumatic brain injury and related-neurodegenerative diseases
T2 - A comprehensive overview
AU - Kattan, Dania
AU - Barsa, Chloe
AU - Mekhijian, Sarin
AU - Shakkour, Zaynab
AU - Jammoul, Maya
AU - Doumit, Mark
AU - Zabala, Maria Camila Pareja
AU - Darwiche, Nadine
AU - Eid, Ali H.
AU - Mechref, Yehia
AU - Wang, Kevin K.
AU - Vaccari, Juan Pablo de Rivero
AU - Munoz Pareja, Jennifer C.
AU - Kobeissy, Firas
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2023/1
Y1 - 2023/1
N2 - Given the ambiguity surrounding traumatic brain injury (TBI) pathophysiology and the lack of any Food and Drug Administration (FDA)-approved neurotherapeutic drugs, there is an increasing need to better understand the mechanisms of TBI. Recently, the roles of inflammasomes have been highlighted as both potential therapeutic targets and diagnostic markers in different neurodegenerative disorders. Indeed, inflammasome activation plays a pivotal function in the central nervous system (CNS) response to many neurological conditions, as well as to several neurodegenerative disorders, specifically, TBI. This comprehensive review summarizes and critically discusses the mechanisms that govern the activation and assembly of inflammasome complexes and the major methods used to study inflammasome activation in TBI and its implication for other neurodegenerative disorders. Also, we will review how inflammasome activation is critical in CNS homeostasis and pathogenesis, and how it can impact chronic TBI sequalae and increase the risk of developing neurodegenerative diseases. Additionally, we discuss the recent updates on inflammasome-related biomarkers and the potential to utilize inflammasomes as putative therapeutic targets that hold the potential to better diagnose and treat subjects with TBI.
AB - Given the ambiguity surrounding traumatic brain injury (TBI) pathophysiology and the lack of any Food and Drug Administration (FDA)-approved neurotherapeutic drugs, there is an increasing need to better understand the mechanisms of TBI. Recently, the roles of inflammasomes have been highlighted as both potential therapeutic targets and diagnostic markers in different neurodegenerative disorders. Indeed, inflammasome activation plays a pivotal function in the central nervous system (CNS) response to many neurological conditions, as well as to several neurodegenerative disorders, specifically, TBI. This comprehensive review summarizes and critically discusses the mechanisms that govern the activation and assembly of inflammasome complexes and the major methods used to study inflammasome activation in TBI and its implication for other neurodegenerative disorders. Also, we will review how inflammasome activation is critical in CNS homeostasis and pathogenesis, and how it can impact chronic TBI sequalae and increase the risk of developing neurodegenerative diseases. Additionally, we discuss the recent updates on inflammasome-related biomarkers and the potential to utilize inflammasomes as putative therapeutic targets that hold the potential to better diagnose and treat subjects with TBI.
KW - Biomarkers
KW - Caspase-1
KW - Inflammasomes
KW - NLPR1
KW - Neurodegenerative diseases
KW - Pyroptosis
KW - Therapeutic targets
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85144780786&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2022.104969
DO - 10.1016/j.neubiorev.2022.104969
M3 - Review article
C2 - 36423707
AN - SCOPUS:85144780786
SN - 0149-7634
VL - 144
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
M1 - 104969
ER -